ArticlePloS one2025
Optimal adaptive cancer therapy based on evolutionary game theory.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- How optimal control of cellular cost shapes population-level tumor growth dynamics.bioRxiv : the preprint server for biology · 2026Article
- Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks.Translational oncology · 2026Review
- In silico models in oncology, neurology, and epidemiology: systems-level and multiscale perspectives.NPJ systems biology and applications · 2026Review
- Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026Review
- Generative AI - Assisted Adaptive Cancer Therapy.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer development is a dynamic and continuously evolving process, with the emergence of drug-resistant cancer cells being one of the primary reasons for the failure of traditional treatments. Adaptive therapy, as an emerging cancer treatment strategy, is increasingly being applied in oncology. In this study, we incorporate pharmacokinetics into a cancer evolutionary game theory model and propose an optimal control problem constrained by maximum drug concentration and maximum tumor burden. Firstly, we demonstrate the existence of an optimal control for this problem. Secondly, using Pontryagin's minimum principle, we formulated the structure of the optimal control to design an optimal adaptive therapy strategy. Finally, through numerical simulations, we compare the optimal adaptive therapy strategy with other adaptive therapies and traditional treatments, and further develop personalized treatment plans for different patient groups. The results demonstrate that the optimized adaptive treatment strategy effectively preserves a high survival rate of healthy cells during treatment. By maintaining drug-sensitive and drug-resistant cell populations in a state of low-level competition, this approach prevents the proliferation of drug-resistant cells, reduces the tumor burden on patients, and extends overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.